

Bibliography—Clinical Efficacy Table of Contents

Glycemic Control.....	4-3
Foot Care	4-5
Eye Care.....	4-7
Renal Disease	4-9
Hypertension and Cardiovascular Disease	4-11
Lipid Management	4-13
Patient Education	4-15

Page intentionally left blank.

GLYCEMIC CONTROL

1. Abaira C, Colwell J, Nuttall, et al. Cardiovascular events and correlates in the VA Feasibility Trial (VACSDM). VA Cooperative Study on Glycemic Control and Complications in Diabetes Mellitus Type II. *Archives of Internal Medicine* (in press).
2. Anderson DKG, Svardsudd K. Long term glycemic control relates to mortality in type II diabetes. *Diabetes Care* 1995;18:1534-43.
3. Arfken CL, Salicrup AE, Meuer SM, et al. Development and progression of retinopathy in African Americans and whites with insulin dependent diabetes. *Archives of Internal Medicine* 1994;154:2597-602.
4. Burden AC, McNally PG, Feehally J, Walls J. Increased incidence of end stage renal disease secondary to diabetes mellitus in Asian ethnic groups in the United States. *Diabetic Medicine* 1992;9:641-5.
5. Chiasson J, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus, a multi center controlled clinical trial. *Annals of Internal Medicine* 1994;121:928-35.
6. Cowie CC, Port FK, Wolfe RA, et al. Disparities in incidence of diabetic end stage renal disease according to race and type of diabetes. *New England Journal of Medicine* 1989;321:1074-9.
7. Cruickshanks KJ, Alleyne SA. Black West Indian and matched white diabetics in Britain compared with diabetics in Jamaica: body mass; blood pressure; and vascular disease. *Diabetes Care* 1987;10:170-9.
8. Danne T, Weber B, Hartmann R, et al. Long term glycemic control has a non-linear association to the frequency of background retinopathy in adolescents with diabetes. *Diabetes Care* 1994;17:1390-6.
9. DCCT Research Group. The effect of intensive insulin treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. *New England Journal of Medicine* 1993;329:977-86.
10. DCCT Research Group. The absence of a glycemic threshold for the development of long term complications: the perspective of the DCCT. *Diabetes* 1996;45:1289-98.
11. DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the DCCT. *Diabetes* 1995;44:968-83.
12. DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of diabetic nephropathy in the DCCT. *Kidney International* 1995;47:1703-20.
13. DeFronzo RA, Goodman AM, the Multi Center Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. *New England Journal of Medicine* 1995;333:541-9.
14. Fonseca VA, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. *Journal of Clinical Endocrinology and Metabolism* 1998;83:3169-76.
15. Haffner SM, Fong D, Stern MP, et al. Diabetic retinopathy in Mexican Americans and non-Hispanic whites. *Diabetes* 1988;37:878-84.
16. Hamman RF, Mayer EJ, Moo-Young GA, et al. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM. San Luis Valley Diabetes Study. *Diabetes* 1989;38:1231-7.
17. Humphrey LL, Ballard DJ, Frohnert PP, et al. Chronic renal failure in non-insulin dependent diabetes mellitus. A population based study in Rochester; Minnesota. *Annals of Internal Medicine* 1989;111:788-96.
18. Kawazu T, Shimizu K, Ohno I, et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin dependent diabetes mellitus. *Journal of Diabetes and its Complications* 1994;8:13-7.

19. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. *Diabetes Care* 1995;18:258-68.
20. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The relationship between hyperglycemia to the long term incidence and progression of diabetic retinopathy. *Archives of Internal Medicine* 1994;154:2169-78.
21. Klein R, Klein B, Moss SE, Cruickshanks KJ. Ten-year incidence and progression of diabetic retinopathy. *Archives of Ophthalmology* 1994;112:1217-28.
22. Klein R, Klein B, Moss SE, Cruickshanks KJ. Ten-year incidence of gross proteinuria in people with diabetes. *Diabetes* 1995;44:916-23.
23. Krolewski AS, Laffel LMB, Krowlewski M, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin dependent diabetes mellitus. *New England Journal of Medicine* 1995;332:1251-5.
24. Lee ET, Lee VS, Lu M, Russell D. Development of proliferative retinopathy in Oklahoma Indians with NIDDM: incidence and risk factors. *Diabetes Care* 1992;15:1620-7.
25. Nelson RG, Newman JM, Knowler WC, et al. Incidence of end stage renal disease in type II (non-insulin dependent) diabetes in Pima Indians. *Diabetologia* 1988;31:730-6.
26. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective six year study. *Diabetes Research and Clinical Practice* 1995;28:103-17.
27. Palmberg P, Smith M, Waltman, et al. The natural history of retinopathy in insulin dependent juvenile onset diabetes. *Ophthalmology* 1981;88:613-8.
28. Panzram G. Mortality and survival in type 2 (non-insulin dependent) diabetes mellitus. *Diabetologia* 1987;30:123-31.
29. Rabb MF, Gagliano DA, Sweeny NE. Diabetic retinopathy in blacks. *Diabetes Care* 1990;13:1202-26.
30. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997;20:1183-97.
31. Singer D, Nathan DM, Anderson K, et al. Association of HbA1C with prevalence of cardiovascular disease in the original cohort of the Framingham Heart Study. *Diabetes* 1992;41:202-8.
32. Stephens GW, Gillaspay JA, Clyne D, et al. Racial differences in the incidence of end stage renal disease in types I and II diabetes mellitus. *American Journal of Kidney Diseases* 1990;15:562-7.
33. UK Prospective Diabetes Study Group (UKPDS 28). A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. *Diabetes Care* 1998;21:87-92.
34. UK Prospective Diabetes Study Group (UKPDS 33). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. *Lancet* 1998;352:837-53.
35. UK Prospective Diabetes Study Group (UKPDS 16). Overview of six years therapy of type II diabetes: a progressive disease. *Diabetes* 1995;44:1249-58.

FOOT CARE

1. American Diabetes Association position statement. Preventive care in people with diabetes. 1999;22 (supplement).
2. American Diabetes Association, Diabetic Foot Care 1990.
3. Ahroni J. Teaching foot care creatively and successfully. *Diabetes Educator* 1993;19:230-4.
4. Bailey TS, Yu HM, Rayfield EJ. Patterns of foot examination in a diabetic clinic. *American Journal of Medicine* 1985;78:371-4.
5. Barth R, Campbell LV, Allen S, et al. Intensive education improves knowledge, compliance, and foot problems in type 2 diabetes. *Diabetic Medicine* 1991;8:111-7.
6. Birke JA, Sims DS. The insensitive foot. In *Physical Therapy of the Foot and Ankle*. Hunt GC, Ed. New York, NY: Churchill Livingstone 1988;133-68.
7. Boyko EJ. A prospective study of risk factors for diabetic foot ulcers. *Diabetes* 1996; Supplement, 194.
8. Brodsky JW, Schneider C. Diabetic foot infections. *Orthopedic Clinics of North America* 1991;22:473-89.
9. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AU. Assessment and management of foot disease in patients with diabetes. *New England Journal of Medicine* 1994;331:854-860.
10. Cavanagh PR, Sanders LJ, Sims DS Jr. The role of pressure distribution measurement in diabetic foot care. *Rehabilitation R&D Progress Reports* 1987.
11. Conte MS. Femorotibial bypass for claudication: do results justify an aggressive approach? *Journal of Vascular Surgery* 1995;21(6):873-81.
12. Currie IC. Treatment of intermittent claudication: the impact on quality of life. *European Journal of Vascular and Endovascular Surgery* 1995;10:356-61.
13. Eckman MH, Greenfield S, Mackey WC, et al. Foot infections in diabetic patients. Decision and cost-effectiveness analyses. *Journal of the American Medical Association* 1995;273:712-20.
14. Fain JA, Melkus GDE. Nurse practitioner practice patterns based on standards of medical care for patients with diabetes. *Diabetes Care* 1994;7:879-81.
15. Feste C. Empowerment: facilitation, a path to responsible self-care. Elkhart, Ind., Miles Inc., Diagnostics Division 1991.
16. Giacalone VF. Phenol matrixectomy in patients with diabetes. *Journal of Foot and Ankle Surgery* 1997;36:264-7.
17. Holewski JJ, Stress RM, Graf PM, Grunfeld C. Anesthesiometry: Quantification of cutaneous pressure sensation in diabetic peripheral neuropathy. *Journal of Rehabilitation Research and Development* 1988;25:1-10.
18. Kumar S, Fernando DJS, Veves A, et al. Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. *Diabetes Research and Clinical Practice* 1991;13:63-8.
19. Lavery LA, Walker SC, Harkless LB, Felder-Johnson K. Infected puncture wounds in diabetic and nondiabetic adults. *Diabetes Care* 1995;18:1588-91.
20. Litzelman DK, Slemenda CW, Langefeld CD. Reduction of lower extremity clinical abnormalities in patients with non-insulin dependent diabetes mellitus. *Annals of Internal Medicine* 1993;19:36-41.
21. Mayfield JA, Reiber GE. A foot risk classification system to predict diabetic amputation in Pima Indians. *Diabetes Care* 1996;19:704-9.

22. Orchard TJ & Strandness ED. Assessment of peripheral vascular disease in diabetes. *Diabetes Care* 1993;16:1199-1209.
23. Pecoraro RE, Reiber GE, Burgess EM. Pathway to diabetic limb amputation. Basis for prevention. *Diabetes Care* 1990;13:513-21.
24. Perry JE, Ulbrecht JS, Derr JA, Cavanagh PR. The use of running shoes to reduce plantar pressures in patient who have diabetes. *Journal of Bone and Joint Surgery (American Volume)* 1995 Dec;77A 77:1819-28.
25. Reiber GE, Boyko EJ, Smith D. Lower extremity foot ulcers and amputations in diabetes. In *Diabetes in America* 2nd Ed. NIH Publication No. 95-1468. 1995;409-27.
26. Rith-Najarian SJ, Stolusky TG, Gohdes DM. Identifying diabetic patients at high risk for lower extremity amputation in a primary health care setting. *Diabetes Care* 1992;15:1386-9.
27. Sims DS Jr, Cavanaugh PR, Ulbrecht JS. Risk factors in the diabetic foot. *The Journal of the American Physical Therapy Association* 1988;68:1887-1902.
28. Steed DL, Donohoe D, Webster MW, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. *Journal of the American College of Surgeons* 1996;183:61-4.
29. Uccioli L, et al. Manufactured shoes in the prevention of diabetic foot ulcers. *Diabetes Care* 1995;18:1376-8.
30. Weir GC, Nathan DM, Singer DE, Technical Review. Standards of care for diabetes. *Diabetes Care* 1994;17:114-22.
31. Wolf GL. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. *Journal of Vascular Interventional Radiology* 1993;4:639-48.
32. Young MJ, Cavanagh PR, Thomas MM, et al. The effect of callus removal on dynamic plantar foot pressure in diabetic patients. *Diabetic Medicine* 1992;9:55-7.

EYE CARE

1. Bonomi L, Marchini G, Marraffa M, et al. Prevalence of glaucoma and intraocular pressure distribution in a defined population: The Egna-Neumarkt Study. *Ophthalmology* 1998;105:209-15.
2. Dasbach EJ, Fryback DG, Newcomb PA, et al. Cost-effectiveness of strategies for detecting diabetic retinopathy. *Medical Care* 1991;29:20-39.
3. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early treatment diabetic retinopathy study report #18. *Investigative Ophthalmology & Visual Science* 1998;39:233-52.
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. *New England Journal of Medicine* 1993;329:977-86.
5. Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the diabetes control and complications trial. *Archives of Ophthalmology* 1998;116:874-86.
6. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision, results of a randomized trial-diabetic retinopathy vitrectomy study report 3. *Ophthalmology* 1988;95:1307-20.
7. Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: diabetic retinopathy study report no. 14. *International Ophthalmology Clinics* 1987;27:239-53.
8. Dibble CM, Kochenour NK, Worley RJ, et al. Effect of pregnancy on diabetic retinopathy. *Obstetrics and Gynecology* 1982;59:699-704.
9. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy, ETDRS report number 9. *Ophthalmology* 1991;98:766-85.
10. Ederer F, Hiller R, Taylor HR. Senile lens change and diabetes in two population studies. *American Journal of Ophthalmology* 1981;91:381-95.
11. Ferris FL. How effective are treatments for diabetic retinopathy? *Journal of the American Medical Association* 1993;269:1290-1.
12. Hemachandra A, Ellis D, Lloyd CE, Orchard TJ. The influence of pregnancy on IDDM complications. *Diabetes Care* 1995;18:950-4.
13. Javitt C, Conner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetes. *Ophthalmology* 1989;96:255-64.
14. Javitt JC, Aiello LP, Chiang Y, Ferris FL, et al. Preventive eye care in persons with diabetes. Cost-saving the federal government: implications for health care reform. *Diabetes Care* 1994; 17:909-16.
15. Kim HK, Kim CH, Kim SW, et al. Development and progression of diabetic retinopathy in Koreans with NIDDM. *Diabetes Care* 1998;21:134-8.
16. Klein R, Moss SE, Klein BEK, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XI: The incidence of macular edema. *Ophthalmology* 1989;96:1501-10.
17. Klein BEK, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. *Diabetes Care* 1990;13:34-40.
18. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Study of Diabetic Retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. *Archives of Ophthalmology* 1984;102:527-32.
19. Klein R, Klein BEK, Moss SE. The Epidemiology of Ocular Problems in Diabetes mellitus. In: Ferman SS, ed. *Ocular Problems in Diabetes Mellitus*. Boston, Blackwell Scientific Publications 1992;1-53.

20. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Study of Diabetic Retinopathy II, Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. *Archives of Ophthalmology* 1984;102:520-6.
21. Klein R, Klein BEK, Moss SE, Cruickshanks KJC. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIV: Ten year incidence and progression of diabetic retinopathy. *Archives of Ophthalmology* 1994;112:1217-28.
22. Klein R, Klein BEK. Vision Disorders in Diabetes. In: National Diabetes Data Group. *Diabetes in America*, 2nd ed, Bethesda, National Institutes of Health 1995;293-338.
23. Klein BEK, Klein R, Jensen SC. Open angle glaucoma and older onset diabetes: the beaver dam eye study. *Ophthalmology* 1994;101:1173-7.
24. Klein R. Hyperglycemia and microvascular and macro vascular disease in diabetes. Kelly West Lecture 1994. *Diabetes Care* 1995;18:258-68.
25. Klein BEK, Klein R, Wang Q, Moss SE. Older onset diabetes and lens opacities: the beaver dam eye study. *Investigative Ophthalmology and Visual Science* 1993;34:1065.
26. Klein R, Moss SE, Klein BEK. Is gross proteinuria a risk factor for the incidence of proliferative diabetic retinopathy? *Ophthalmology* 1993;100:1140-6.
27. Mason RP, Kosoko O, Wilson MR, et al. National Survey of the Prevalence and Risk Factors of Glaucoma in St. Lucia, West Indies. Part I: Prevalence findings. *Ophthalmology* 1989;96:1363-8.
28. Moss SE, Klein R, Kessler SD, Richie KA. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. *Ophthalmology* 1985;92:62-7.
29. Nakagami T, Kawabara R, Hori S, Omori Y. Glycemic control and prevention of retinopathy in Japanese NIDDM patients: A 10-year follow up study. *Diabetes Care* 1997;20:621-2.
30. Nathan DM, Fogel HA, Godine JE, et al. Role of diabetologist in evaluating diabetic retinopathy. *Diabetes Care* 1991;14:26-33.
31. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: A randomized prospective 6-year study. *Diabetes Research Clinical Practice* 1995;28:103-17.
32. Savage S, Estacio R, Jeffers B, Schrier R. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. *Diabetes Care* 1996;19:1243-8.
33. Sommer A, Tielsch JM, Katz J, Quigley HA, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: The Baltimore Eye Survey. *Archives of Ophthalmology* 1991;109:1090-5.
34. Sperduto RD, Hiller R, Chew E, et al. Risk Factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion. The Eye Disease Case Control Study. *Ophthalmology* 1998;105:765-71.
35. Tielsch JK, Katz J, Quigley HA, et al. Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore eye survey. *Ophthalmology* 1995;102:48-53.
36. Tielsch JM, Katz J, Sommer A, et al. Family history and risk of primary open-angle glaucoma: the Baltimore eye survey. *Archives of Ophthalmology* 1994;112:69-73.
37. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore eye survey. *Journal of the American Medical Association* 1991;266:369-74.
38. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. *Lancet* 1998;352:837-53.

RENAL DISEASE

1. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. *Diabetes Care* 1997;20:1576-81.
2. American Diabetes Association. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. *Diabetes Care* 1994;17:1357-61.
3. American Diabetes Association. Position statement: diabetic nephropathy. *Diabetes Care* 1997;20(S1):S24-27.
4. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 1995;18:8-15.
5. Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. *American Journal of Kidney Diseases* 1995;25:107-12.
6. Ciavarella A, Di Mizio G, Stefoni S, et al. Reduced albuminuria after dietary protein restriction in insulin-dependent diabetic patients with clinical nephropathy. *Diabetes Care* 1987;407-13.
7. Evanoff G, Thompson C, Brown J, Weinman E. Prolonged dietary protein restriction in diabetic nephropathy. *Archives of Internal Medicine* 1989;149:1129-33.
8. Gall M, Rossing P, Skott P, et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type II diabetic patients. *Diabetologia* 1991;34:655-61.
9. Harris MI. Classification, Diagnostic Criteria and Screening for Diabetes. Chapter 2. In: Harris MI (Ed.) *Diabetes in America*. Second edition. Bethesda, MD 1995.
10. Hasslacher C. Hypertension as a risk factor in non-insulin dependent diabetes mellitus: how far should blood pressure be reduced? *Journal of Diabetes and its Complications* 1997;11:90-1.
11. Howey JEA, Browning MCK, Fraser CG. Biologic variation of urinary albumin: consequences for analysis, specimen collection, interpretation of results, and screening programs. *American Journal of Kidney Diseases* 1989;13:35-7.
12. Kasiske BL, Lakatua JD. The effects of dietary protein restriction on chronic progressive renal disease. *Mineral & Electrolyte Metabolism* 1997;23:296-300.
13. Kouri TT, Viikari JSA, Mattila KS, Irjala KMA. Microalbuminuria: invalidity of simple concentration-based screening tests for early nephropathy due to urinary volumes of diabetic patients. *Diabetes Care* 1991;14:591-3.
14. Marre M, Chatellier G, Leblanc H, et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. *British Medical Journal* 1988;297:1092-2005.
15. Mogensen CE. Renoprotective role of ACE inhibitors in diabetic nephropathy. *British Heart Journal* 1994;72 (Supp):38-45.
16. Mogensen CE. Microalbuminuria is a predictor of clinical diabetic nephropathy. *Kidney International* 1987;31:673-89.
17. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. *Lancet* 1995;346:1080-4.
18. Murray JE. Microalbuminuria in type II diabetes. *Endocrine Practice* 1996;2:211-4.
19. Nelson RG, Knowler WC, Pettitt DJ, Bennett PH. Chapter 16 Kidney Diseases in Diabetes. In Harris MI (Ed.) *Diabetes in America*. Second edition. Bethesda, MD 1995.

20. Nielson FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. *Diabetes* 1997;46:1182-8.
21. Ordonez JD, Hiatt RA. Comparison of type II and type I diabetics treated for end-stage renal disease in a large prepaid health plan population. *Nephron* 1989;51:524-9.
22. O'Donnell MJ, Rowe BR, Lawson N, et al. Placebo controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. *Journal of Human Hypertension* 1993;7:327-32.
23. Pedrini MT, Levey AS, Lau J, et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. *Annals of Internal Medicine* 1996;124:627-32.
24. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus, a seven-year follow-up study. *Archives of Internal Medicine* 1996;156:286-9.
25. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. *Annals of Internal Medicine* 1993;118:577-81.
26. Roca-Cusachs A. Lowering blood pressure: How far? How fast? *Drugs* 1993;46:8-15.
27. Romero R, Salinas I, Lucas A, et al. Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors. *Diabetes Care* 1993;16:597-600.
28. Schrier RW (Ed.). *Renal and electrolyte disorders*. Little, Brown and Company. Boston, MA 1976;326.
29. Walker JD, Dodds RA, Murrells TH, et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. *Lancet* 1989;ii:1411-5.
30. Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. *New England Journal of Medicine* 1991;324:78-84.

HYPERTENSION AND CARDIOVASCULAR DISEASE

1. American College of Sports Medicine. ACM's guidelines for exercise testing and prescription. Fifth Ed. Baltimore, MD: Williams & Wilkins, 1995.
2. American Heart Association. An Active Partnership for the Health of Your Heart. American Heart Association. Dallas, TX 1990.
3. Byington RP, Furberg CD, Craven TE, et al. Isradepine in prediabetic hypertensive subjects. *Diabetes Care* 1998;21:2103-10.
4. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. *American Journal of Cardiology* 1998;82:9R-14R.
5. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in persons with NIDDM and HTN. *New England Journal of Medicine* 1998;338:645-52.
6. Hansson L, Zanchetti A, Carruthers SG, et al, for the Hypertension Optimal Treatment (HOT) Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the HOT randomized trial. *Lancet* 1998;351:1755-62.
7. National High Blood Pressure Education Program Working Group. Report on HTN in diabetes. *Hypertension* 1994;23:152.
8. Merlo J, et al. Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs: population based cohort study. *British Medical Journal* 1996;313:457-61.
9. Pharmacy Benefits Management (Medical Advisory Panel) The pharmacological management of hypertension. VHA PBM-SHG Publication No. 96-0003. Hines, IL: Pharmacy Benefits Management Strategic Health Group, Veterans Health Administration, Department of Veterans Affairs. December 1996.
10. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in persons with hypertension and NIDDM. *Diabetes Care* 1998;21:597-603.
11. The Sixth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. *Archives of Internal Medicine* 1997;157:2413-46.
12. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. *New England Journal of Medicine* 1999;340:677-84.
13. UK Prospective Diabetes Study Group (UKPDS 38). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. *British Medical Journal* 1998;317:703-13.
14. UK Prospective Diabetes Study Group (UKPDS 39). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. *British Medical Journal* 1998;317:713-20.
15. US Department of Health & Human Services. National Health Promotion and Disease Prevention Objectives. *Health People 2000*. Washington, DC 1991. DHHS (PHS) publication 91-50212.
16. US Preventive Services Task Force. Guide to Clinical Preventive Services. Second Ed. Baltimore, MD: Williams & Wilkins, 1996.

Page intentionally left blank.

LIPID MANAGEMENT

1. Avins AL, Browner WS. Lowering risk without lowering cholesterol: implications for national cholesterol policy. *Annals of Internal Medicine* 1996;125:502-6.
2. Behounek BD, McGovern ME, Kassler-Taub KB, et al. A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hyper-cholesterolemia. *Clinical Cardiology* 1994;17:558-62.
3. Campeau L, Knatterud L, Damanski M, et al. The effect of aggressive lowering of low density lipoprotein cholesterol levels and low-dose anticoagulation of obstructive changes in saphenous-vein coronary-artery bypass grafts. *New England Journal of Medicine* 1997;336:153-62.
4. Danese MD, Powe NR, Sawin CT, Ladenson PW. Screening for mild thyroid failure at the periodic health examination. A decision and cost-effective analysis. *Journal of the American Medical Association* 1996;276:285-92.
5. Demacker PNM, Toenhake-Dijkstra H, de Rijke YB, et al. On the presumed inaccuracy of the Friedewald formula in hypertriglyceridemic plasma: a role for imprecise analysis? *Clinical Chemistry* 1996;42:1491-4.
6. Garber AM, Browner WS, the American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. *Annals of Internal Medicine* 1996;124:515.
7. Haffner SM. Management of dyslipidemia in adults with diabetes. (Technical Review). *Diabetes Care* 1998;21:160-78.
8. Jeck T, Riesen WF, Keller U. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM. *Diabetic Medicine* 1996;14:564-70.
9. Kreisberg RA. Cholesterol-lowering and coronary atherosclerosis: good news and bad news. *American Journal of Medicine* 1996;101:455-8.
10. Krolewski AS, Warram JH, Freire MBS. Epidemiology of late diabetic complications. A basis for the development and evaluation of preventive programs. *Endocrinology Metabolism Clinics of North America* 1996;25:217-42.
11. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. *Journal of the American Medical Association* 1994;272:1335-40.
12. Laakso M. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin- dependent diabetes mellitus. *Annals of Internal Medicine* 1996;28:341-5.
13. Marchioli R, Marfisi RM, Carinci F, Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. *Archives of Internal Medicine* 1996;156:1158-72.
14. Nauck M, Kramer-Guth A, Bartens W, et al. Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients? *Clinical Nephrology* 1996;46:319-25.
15. Pedersen TR, the Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344:1383.
16. Pharmacy Benefits Management (Medical Advisory Panel). The Pharmacologic Management of Hyperlipidemia. VHA PBM-SHG Publication No. 96-0002. Hines, IL: Pharmacy Benefits Strategic Health Group, Veterans Health Administration, Department of Veterans Affairs. December 1996.

17. Pyorala K, Steiner G. Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence. *Annals of Internal Medicine* 1996;28:357-62.
18. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. *Diabetes Care* 1997;20:614-20.
19. Ramsey LE, Haq IU, Jackson PR. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. *Lancet* 1996;348:387.
20. Ramsey LE, Haq IU, Jackson PR. The Sheffield table for primary prevention of coronary heart disease: corrected. *Lancet* 1996;348:1251.
21. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. *New England Journal of Medicine* 1996;335:1001-9.
22. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *New England Journal of Medicine* 1995;333:1301-7.
23. Sweany AE, Shapiro DR, Tate AC, et al. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin dependent diabetes mellitus. NIDDM Study Group. *Clinical Therapeutics* 1995;17:186-203.

PATIENT EDUCATION

1. A Diabetic Education Pilot Program Experience 1/1/83-6/30/83. Blue Cross/Blue Shield of North Dakota.
2. Anderson RM, Funnell MM, Butler PM, et al. Patient empowerment. Results of a randomized controlled trial. *Diabetes Care* 1995;18:943-9.
3. Agurs-Collins TD, Kumanyika SK, Ten-Have TR, Adams-Campbell LL. A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects. *Diabetes Care* 1997;20:1503-11.
4. Alogna M, CDC Diabetes Control Programs-Overview of Diabetes Patient Education. *Diabetes Educator*, Winter 1985;10:32-6. (State of Rhode Island and Saginaw County Michigan Programs)
5. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 1999;22 Supplement 1:35.
6. American Diabetes Association. Meeting the Standards. Standard 12. National Standards for Diabetes Education Program Recognition Application Manual, 1998.
7. Aubert RE, Herman WH, Waters J, et al. Nurse case management to improve glycemic control in a diabetic patients in a health maintenance organization. A randomized controlled trial. *Annals of Internal Medicine* 1998;129:605-712.
8. Brink S, Siminerio L, Hinnen-Hentzen D, et al. Diabetes Education Goals. Alexandria, VA: American Diabetes Association, Inc., 1995:63.
9. Coonrod BA, et al. Frequency and determinants of diabetes patient education among adults in the US population. *Diabetes Care* 1994;17:852-8.
10. Davidson JK, et al. Spin-off cost benefits of expanded nutritional care. *Journal of the American Dietetic Association* 1979;75:250-7.
11. DCCT Research Group. The effects of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *New England Journal of Medicine* 1993;329:977-86.
12. DCCT Research Group. Expanded role of the dietitian in the diabetes control and complications trial: Implications for clinical practice. *Journal of the American Dietetic Association*. 1993;93:758-67.
13. DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. *American Journal of Medicine* 1991;90:450-9.
14. Evaluation of the State of Maryland's Diabetes Care Program, Baltimore County Center for Health Program Development and Management. University of Maryland, 1995.
15. Franz MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin dependent diabetes mellitus: A randomized, controlled clinical trial. *Journal of the American Dietetic Association* 1995;95:1009-17.
16. Franz MJ, Splett PL, Monk A, et al. Cost-effectiveness of medical nutrition therapy provided by dietitians for persons with non-insulin dependent diabetes mellitus. *Journal of the American Dietetic Association* 1995;95:1018-24.
17. Jaber LA, Halapy H, Fernet M, et al. Evaluation of a pharmaceutical care model on diabetes management. *Annals of Pharmacotherapy* 1996;30:238-43.
18. Jacobson JM, et al. Impact of a diabetes teaching program on health care trends in an Air Force Medical Center, *Military Medicine* 1983;148:46-7.

19. Larne AC & Pugh JA. Attitudes of primary care providers toward diabetes: barriers to guideline implementation. *Diabetes Care* 1998;21:1391-6.
20. Lustma PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized controlled trial. *Annals of Internal Medicine* 1998;129:8, 613-21.
21. McGlynn Margaret. Senior Vice President of Merck-Medco Managed Care Inc., Testimony before the Senate Special Committee on Aging, March 28, 1996—Outcomes Study Review.
22. Medical Nutrition Across the Continuum of Care. The American Dietetic Association, Chicago Illinois, 1998.
23. Merritt JG, et al. Outcome analysis of a diabetic education clinic. *Military Medicine* 1983;148:545-7.
24. Miller LV, et al. More efficient care of diabetes in a county hospital setting. *New England Journal of Medicine* 1972;286:1388-91.
25. Miller ST, et al. Evaluation of decentralized system for chronic disease care: seven years of observation. *American Journal of Public Health* 1980;70:401-5.
26. Muhlhauser I, et al. Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients; improvement of metabolic control and other measures of diabetes care for up to 22 months. *Diabetologia* 1985;25:470-6.
27. National Diabetes Advisory Board, National Standards for Diabetes Patient Education Programs. *Diabetes Care* 1983;7:xxxii-xxxv.
28. Padgett D, Mumford E, et al. Meta-analysis of the effects of educational and psychosocial interventions on management of diabetes mellitus. *Journal of Clinical Epidemiology* 1988;41:1007-30.
29. Perry TL, Mann JI, Lewis-Barned, et al. Lifestyle intervention in people with insulin-dependent diabetes mellitus (IDDM). *European Journal of Clinical Nutrition* 1997;51:757-63.
30. Peters A, et al. Quality of care for patients with diabetes in HMO settings in California (Abstract) May 1995.
31. Report of the Task Force on the Delivery of Diabetes Self-Management Education and Medical Nutrition Therapy, American Diabetes Association Task Force 4/21/98.
32. Rubin RJ, et al. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care. *Journal of Clinical Endocrinology and Metabolism* 1998;83:2635-42.
33. State of Maine, DHHS Reimbursement Pilot Study for the Ambulatory Diabetic Education and Follow-up (ADEF) Program: Final Report August 1983.
34. Scheffler RM, et al. Prevention: the cost effectiveness of the California diabetes and pregnancy program. *American Journal of Public Health* February 1992;82:168-75.
35. Self-Management Education Programs and American Diabetes Association Review Criteria. *Diabetes Care* 1999;22 Supplement 1:111-4.
36. Sikka R, Waters J, Moore W, et al. Renal assessment of practices and the effect of nurse case management of health maintenance organization patients with diabetes. *Diabetes Care* 1999;22:1-6.
37. United States, Department of Health and Human Services, Healthy People 2000, DHHS publication no. (PHS) 91-50212, 1992.